MedTrace Logo

Longitudinal Quantitative Susceptibility Mapping (QSM) in Alzheimer 's Disease

NCT02752750 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-09-21

No results posted yet for this study

Summary

In this explorative longitudinal study 50 patients with Alzheimer's disease (AD) and 50 age-matched control subjects will be recruited for their 2 years follow-ups and undergo extensive cognitive testing and quantitative 3 Tesla magnetic resonance imaging (MRI). Regional differences of susceptibility and R2\* relaxation rates in deep gray matter and the neocortex will be evaluated in AD patients and controls and related to the patients´ cognitive status at baseline.

Conditions

Interventions

OTHER

MRI

MR imaging (MRI) at 3 Tesla

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Christian Langkammer, PhD · Medical University of Graz

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2024-05-31
Completion
2025-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02752750 on ClinicalTrials.gov